POLYMEDNSEPoly Medicure Limited· PharmaceuticalsHighNeutral
Announced Mon, 25 May · 15:22 IST

Poly Medicure Limited has submitted to the Exchange, the Audited financial results(Standalone & Consolidated) for the quarter and year ended March 31, 2026.

Revenue Growth 20pctPat NegativeExceptional ItemResults View source PDF

POLYMED · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-10.2%1-day move
₹1600.00
prior close
₹1601.10
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-4.9-10.2-17.2-15.6-17.2-17.4-11.6-5.4+3.1+4.7
Up moveDown movePending
AI summary

Poly Medicure Limited reported FY2026 standalone revenue of Rs 4,448.44 lakhs with net profit after tax of Rs 3,359.85 lakhs, marginally higher than Rs 3,313.35 lakhs in FY2025. On a consolidated basis, revenue grew significantly to Rs 5,522.68 lakhs (up 21.2% from Rs 4,651.38 lakhs) driven by acquisitions of Pendracare Group and Medstream SA (Citieffe Group). However, consolidated net profit declined to Rs 3,207.30 lakhs from Rs 3,385.57 lakhs in the prior year. The Board recommended a dividend of Rs 3.5 per share (70% payout). An exceptional item of Rs 680.40 lakhs was recorded due to the impact of new Labour Codes. Statutory auditors issued unmodified audit opinions on both standalone and consolidated financial results.

Likely market impact

The company delivered strong consolidated revenue growth from acquisitions, but profitability declined on a consolidated basis due to acquisition-related costs and integration expenses. The dividend payout signals management confidence, though shareholders should monitor margin recovery in coming quarters.